Christopher Hourigan, MD, PhD, associate professor at Johns Hopkins and principal investigator at the National Heart, Lung, and Blood Institute of the National Institutes of Health, highlights his recent work on using measurable residual disease (MRD) to guide acute myeloid leukemia (AML) treatment. Using next-generation sequencing, Dr. Hourigan analyzed MRD from previously banked BMT CTN 0901 clinical trial samples. Dr. Hourigan's work provides the first evidence that intervention on a MRD-positive case using myeloablative conditioning prior to allogeneic hematopoietic cell transplantation (alloHCT) can improve survival.

Learn more by clicking here.